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REVIEW
Retroperitoneoscopic adrenalectomy in
pheochromocytoma
Marcelo Hisano, Fabio Carvalho Vicentini, Miguel Srougi
Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo.
Since the first laparoscopic adrenalectomy, the technique has evolved and it has become the standard of care for
many adrenal diseases, including pheochromocytoma. Two laparoscopic accesses to the adrenal have been
developed: transperitoneal and retroperitoneal. Retroperitoneoscopic adrenalectomy may be recommended for the
treatment of pheochromocytoma with the same peri-operative outcomes of the transperitoneal approach because
it allows direct access to the adrenal glands without increasing the operative risks. Although technically more
demanding than the transperitoneal approach, retroperitoneoscopy can shorten the mean operative time, which is
critical for cases with pheochromocytoma where minimizing the potential for intra-operative hemodynamic
changes is essential. Blood loss and the convalescence time can be also shortened by this approach. There is no
absolute indication for either the transperitoneal or retroperitoneal approach; however, the latter procedure may
be the best option for patients who have undergone previous abdominal surgery and obese patients. Also,
retroperitoneoscopic adrenalectomy is a good alternative for treating cases with inherited pheochromocytomas,
such as multiple endocrine neoplasia type 2A, in which the pheochromocytoma is highly prevalent and frequently
occurs bilaterally.
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INTRODUCTION
Pheochromocytoma (PHEO) is a neuroendocrine tumor
that derives from chromaffin cells of the adrenal medulla
(1). It is a challenging disease that can be cured by removing
the affected adrenal gland (2). Open adrenalectomy has
been the standard of care in this situation (1). Laparoscopic
adrenalectomy was first described in 1992 by Gagner et al.
(3) using the transperitoneal approach. Since then, the
procedure has been continuously developed and has
become the gold standard of care (4–6). Laparoscopic
adrenalectomy has evolved from the transperitoneal
approach to the retroperitoneal approach, and even single-
site access and natural orifice transluminal endoscopic
surgery (NOTES) have been developed (7–10).
Retroperitoneoscopy was first described in 1969 by Bartel
(11) as a diagnostic tool. In the following years, it has
evolved to a minimally invasive diagnostic procedure and
finally became a useful route for operative procedures by
the early 90s (12–15).
Retroperitoneoscopic adrenalectomy was developed in 1993
(16), initially only for small benign lesions and recently for
lesions .5 cm and even malignancies (17). This technique
gained popularity because it allows direct access to the gland
and avoids unexpected lesions to intra-abdominal organs. In
some academic centers (18), it has become the surgery of
choice for adrenalectomy, although it requires a strict working
space and an unusual anatomical recognition compared with
transperitoneal access.
Of note, retroperitoneal adrenalectomy may be especially
useful for treating cases with inherited PHEO, especially
those with multiple endocrine neoplasia type 2 (MEN2A) in
which PHEO frequently occurs concomitantly with medul-
lary thyroid carcinoma and primary hyperparathyroidism.
The prevalence of PHEO with MEN2A is 50% and
frequently occurs bilaterally (50–60%), either synchronic or
asynchronically (19). Recently, PHEO was reported to be
highly prevalent in MEN2A patients harboring the double
634/791 mutation in the RET proto-oncogene (20).
In the present paper, we briefly described the revised
retroperitoneoscopic adrenalectomy technique and the out-
comes of adrenal lesions that have been operated on using
this approach.
Surgical technique
After confirming the diagnosis of PHEO, the patient
needs to be clinically prepared for adrenalectomy in order
to avoid the possibility of a dangerous intraoperative
adrenal crisis. This preparation usually requires at least 4–
6 weeks of using either amlodipine, or preferentially
prazosin, a selective a1-antagonist. Initially, 1 mg/day is
given at bedtime for 10–15 days. Then, 1 mg of prazosin
should be added for 7–10 days until a dose of approximately
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10 mg is reached. Prazosin has a short effective lifespan and,
thus, should be given two or three times a day. Also, the
ingestion of large amounts of liquids (.2.5 L/day) and a
salty diet in order to expand the extracellular volume and
avoid possible postsurgical hypotension or even hypovo-
lemic shock is recommended (21,22). b-adrenoceptor
antagonists (e.g., propanolol) should be added only 2–3
days before surgery, if necessary (e.g., the occurrence of
tachycardia) (1,2,23). Usually, computerized tomography or
magnetic resonance imaging has been already performed
during the diagnostic phase of PHEO and will be useful for
choosing specific surgical techniques. For the success of the
surgical procedure, it is crucial to obtain a careful surgical
history of all PHEO patients who are candidates for
retroperitoneoscopic adrenalectomy. The reason for this is
because a previous retroperitoneal intervention may repre-
sent a relative contraindication for this procedure.
Conversely, previous upper abdominal surgery can make
the procedure more attractive.
Surgery is performed with the patient under general
anesthesia, with laryngeal intubation and assisted ventila-
tion. A peripheral arterial line and a central venous catheter
are inserted for cardiovascular control in all cases. An
orogastric tube is routinely placed for the procedure only.
The bladder remains empty by using a Foley catheter
(RU¨SCHH, Teleflex).
There are two basic positions that the patient should be
placed into for a retroperitoneocopic adrenalectomy: the
lateral posterior and the prone position (24–28), and the
surgeon should choose which position he/she prefers. In
the lateral position, the patient is placed in total lateral
decubitus with hyperextension of the affected side by
elevating the lumbar bridge of the table and straightening
the ipsilateral lower extremity in order to increase the space
between the 12th costal arch and the iliac crest (18,28,29)
(Figure 1). In the prone position, the patient is placed in a
half-jackknife position, with the hip, joints and knees bent at
75–90˚ (Figure 2). The aim of this position is to increase the
space between the last rib and the iliac crest.
The first incision is usually made just below or at the tip of
the last rib, and the retroperitoneal space is reached by sharp
or blunt dissection of the abdominal wall. A retroperitoneal
space can be created using the index finger or balloon
dissection, and the latter option is more suitable for obese
patients. Other ports can be placed under finger guidance or
by retroperitoneoscopic direct vision. A Hasson-type trocar
or a blunt-tip trocar (BLUNT TIPH, Covidien) with an
inflatable balloon can be used during the first incision in
order to avoid or minimize gas leakage. The distribution of
the laparoscopic ports varies among different institutions,
and the endoscopic angle depends on the preference of the
surgeon. Care should be taken to avoid the subcostal nerves.
CO2 pressure can usually be maintained between 10 and
15 mmHg, although a CO2 pressure of 20–25 mmHg can be
safely applied for patients in the prone position (30).
After reaching the retroperitoneum, the surgical tactics
involve the identification of psoas muscle for special
orientation and either vascular access to the adrenal gland
by following the inferior vena cava (on the right side) or the
renal vein (on the left side), or posterior access to the
adrenal by opening Gerota’s fascia, mainly for the prone
position. For the right side, the adrenal vein is usually
situated posterolaterally to the inferior vena cava (Figure 3);
for the left side, the adrenal vein is usually located on the
upper surface of the renal vein (Figure 4). In case of PHEO,
it is recommended to perform an early ligation of the main
adrenal vein in order to minimize potential intraoperative
hypertension due to catecholamine release during adrenal
manipulation (31–33). Alternatively, some prefer to dissect
the gland before adrenal vein ligation (34–36). The inferior
and medial aspects of the gland are then dissected, and the
small inferior and medial adrenal arteries and veins are
separated by clips or sectioned using ultrasonic scissors
(Figures 5 and 6). It is important to always avoid direct
gland and tumor manipulation during the dissection. The
superior aspect of the gland is dissected, followed by the
lateral aspects, which are usually poorly vascularized. The
specimen is extracted through the first incision using an
appropriate retrieval bag system. Placing an aspirative drain
for the retroperitoneal space is optional, and the trocars are
removed under retroperitoneoscopic observation. The fascia
of the port sites that are more than 10 mm are closed,
followed by skin closure using an absorbable material.
RESULTS
There are few studies concerning the retroperitoneal
approach to treat adrenal PHEO, although most of them are
not exclusively related to PHEO cases. Earlier studies were
based on case series to show the feasibility and safety of this
type of treatment. Also, comparative studies of the transper-
itoneal and retroperitoneal routes, and between the open and
retroperitoneal routes, are available, as commented below.
Clinical series
Laparoscopy itself has been shown to be a safe procedure
and does not increase the cardiovascular risk of treating
patients with PHEO (37–39). Some studies do not report any
difference between open and laparoscopic approaches
in regards to intraoperative hemodynamic changes and
Figure 1 - Lateral position. The patient is placed in a hyperexten-
sion position. 1 – first incision is made below the last rib to create
a retroperitoneal space; 2 – second port, 1 cm above the iliac
crest, where the 0˚ endoscope enters; 3 – working port located
4 cm anterior to trocar number 2.
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complications (37). Nau et al. (38) compared these para-
meters for the transperitoneal laparoscopic approach to treat
PHEO and other adrenal diseases and detected only an
increased use of antihypertensive drugs during the proce-
dure for patients with PHEO (p,0.001). They did not find
any other increased cardiovascular risk or complication in
this group, even when considering the fact that PHEO
patients present a significantly higher classification accord-
ing to the American Society of Anesthesiologists (ASA)
(p,0.001). It is important to stress that hypertension must be
controlled before the procedure in order to achieve a
positive clinical outcome.
Walz et al. described a series of 560 retroperitoneal
adrenalectomies that were performed via the posterior
approach; 119 of the procedures were for PHEO (30). The
mean operative time of all of these cases was 67 min; the
operative time for PHEO was significantly longer than for
other adrenal diseases (80 vs. 62 min, respectively; p,0.001).
There was one conversion to the laparoscopic lateral
approach due to severe obesity among the PHEO cases.
Overall, intraoperative complications were noticed in 4.2%
of cases; severe bleeding that required a transfusion
occurred in one patient who was undergoing a partial
adrenalectomy. The main complication encountered during
follow-up was hypoesthesia or relaxation of the abdominal
wall in 8.5% of the 560 cases.
In 2007, Zhang et al. (18) published a series of 824
retroperitoneoscopic adrenalectomies that were performed
via the lateral retroperitoneal approach, of which 62 of these
procedures were for PHEO. In these cases, there was one
conversion to open surgery (1.6%) due to large lesions and
adhesions. The mean operative time for all of these cases
was 45 min. No major bleeding or transfusion was reported.
A prospective study conducted by Walz et al. (39) treated
both PHEO and paraganglioma patients. Of 161 treated
tumors, 113 (70.2%) were unilateral PHEOs that were
treated by retroperitoneoscopy. The median operative time
in these cases was 82 min (range: 20–300 min); for the first
half of these patients, the median time for the procedure
was 110 min, but the second half required only 55 min
(p,0.001).
Li et al. (36) described the largest retrospective series
specifically for describing lateral retroperitoneoscopic adre-
nalectomy that included 131 procedures, including 11 for
extra-adrenal PHEO. The authors divided their experiences
into three phases and compared their laparoscopic data to
open-access cases. In the first phase, laparoscopy accounted
for 37% of the cases, and in the third phase laparoscopy was
responsible for 83% of the cases. The median operative
times in the first, second, and third phases were 105, 85, and
75 min, respectively. Median blood loss in the same phases
was 450, 140, and 70 mL, respectively. Fourteen patients
(10.7%) had no complications and most of them (71.4%)
were considered Clavien grade I complications.
Comparative Studies
A non-randomized retrospective study comparing retro-
peritoneal access to the open approach for adrenal PHEO
(40) reported statistical differences that favored the retro-
peritoneal access when comparing mean blood loss (140 vs.
592 ml, p,0.05), mean hospital stay (4.4 vs. 9.8 days,
p,0.05), and analgesic requirements. The authors concluded
that, although technically demanding, retroperitoneoscopic
adrenalectomy is a good option for the treatment of PHEO.
Other studies have compared the transperitoneal and
retroperitoneal routes for adrenalectomy, but not specifi-
cally for PHEO cases. Baba et al. (41) compared three
approaches for reaching the adrenal gland: transperitoneal,
lateral retroperitoneal, and lumbar retroperitoneal access.
The lumbar approach demonstrated the shortest average
operative time: 142 versus 194 min for the lateral retro-
peritoneal route and 252 min for the transperitoneal route
(p,0.02). Of note, the first alternative allows direct access to
the gland, with no need to retract other abdominal or
retroperitoneal organs. Furthermore, blood loss was sig-
nificantly lower for both lateral retroperitoneal (22 ml) and
lumbar access (32 ml) than transperitoneal access (101 ml)
(p,0.01). In 1998, Miyake et al. (42) retrospectively
compared these surgical routes of access and verified that
operative times were longer and postoperative pain was
higher for transperitoneal laparoscopy, although there was
no statistical difference. Suzuki et al. (24) compared three
different approaches to the adrenal gland: anterior transper-
itoneal, lateral transperitoneal, and lateral retroperitoneal.
They found a mean operative time of 175, 118, and 176 min,
respectively. The lateral transperitoneal approach was
significantly favored (p,0.0001). No significant difference
was found regarding blood loss. Shoulder pain and
paralytic ileus occurred in patients of all groups, but in
the retroperitoneal approach it occurred only when the
peritoneum was opened. Suzuki et al. (24) recommended
that experienced surgeons should treat small lesions using
Figure 2 - Prone position. The patient is placed in a half-jackknife position with the hip, joints and the knees bent 75–90 .˚ Trocar
disposition and camera entrance are illustrated.
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the minimally invasive retroperitoneal approach to avoid
complications related to peritoneum insufflation.
Other authors did not find any significant differences
regarding transperitoneal versus retroperitoneal access.
Fernandez-Cruz et al. (43) documented no difference
regarding blood loss or hemodynamic parameters between
both approaches, in addition to operative time, blood loss
and complications. Gockel et al. (33) reported that the
median operative time is lower in the transperitoneal
approach (85 min) compared with the retroperitoneal
approach (120 min) (p,0.001), particularly when the right
side was compared. Also, a shorter learning curve was
observed for the transperitoneal approach compared with
the retroperitoneal approach. These results were explained
by earlier recognition of anatomic landmarks during
transperitoneal access.
Rubinstein et al. (44) conducted a randomized prospective
comparison between transperitoneal and retroperitoneal
routes for adrenalectomy. Patients from both groups were
comparable with respect to age, body mass index, tumor
size, and ASA classification, and no significant differences
were noticed. Thus, median operative time, blood loss, and
specimen weight were similar in both groups, as well as
analgesic requirements, hospital stay, and complication
rates. The mean convalescence time was 4.7 weeks for the
transperitoneal approach and 2.3 weeks for the retroper-
itoneal approach (p= 0.02). Two patients in the transper-
itoneal group developed with port site-related hernias.
A retrospective study comparing the transperitoneal and
retroperitoneal approaches for treating PHEO analyzed 99
patients with unilateral adrenal lesions and comparable
demographic data (45). There were 40 patients in the
transperitoneal group and 59 in the retroperitoneal group.
The mean operative time (117 vs. 84 min, respectively;
p,0.05), blood loss (340 vs. 200 ml, respectively; p,0.05),
hospital stay (7.8 vs. 4.8 days, respectively; p,0.05), and
complication rates were significantly higher in the transper-
itoneal group. Blood pressure fluctuations, long-term blood
pressure control, metabolic and imaging follow-up were
similar in both groups; however, the recurrence rates were
not verified.
Special situations
Previous abdominal surgery or radiation therapy does not
seem to affect the clinical outcome of the retroperitoneal
approach. Viterbo et al. (46) compared retroperitoneal
access to the kidneys and adrenals in patients with and
without previous abdominal surgery but was unable to
verify significant differences regarding operative time,
blood loss, or convalescence. Retroperitoneal access is the
preferred route for patients with a history of prior
abdominal surgery as a way for surgeons to avoid visceral
and vascular complications (10,28,44,47,48).
Obese patients with PHEO can be preferentially managed
with retroperitoneoscopic adrenalectomy. There are two
reported cases that clearly document the feasibility and
relative safety of this approach (49,50). Because of the direct
access to the gland, some authors consider obesity as an
indication to perform the retroperitoneal approach (28,44,51).
A high body mass index is correlated with a longer operative
time, mainly for those .25 kg/m2 (33,51).
Tumor size must also be taken into consideration when
planning the surgical approach. Due to more restricted
space, retroperitoneoscopy is usually indicated when
adrenal tumors are ,7 cm (43,52), although some experi-
enced centers have operated on larger tumors (18,30,53,54).
Figure 3 - Right-side retroperitoneoscopic view. AV: adrenal vein. IVC: inferior vena cava. P: psoas muscle.
Figure 4 - Left-side retroperitoneoscopic view. A: adrenal. AV: adrenal vein. LV: lumbar vein. RA: renal artery. RV: renal vein. Note the
laparoscopic clips for the inferior and medial adrenal arteries.
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For both approaches, tumor size .5 cm can increase the
operative times (33,55). When there is suspicion of malig-
nant PHEO, the surgical procedure must be considered. In
such cases, the open procedure should be favored over the
laparoscopic approach (56), mainly if radiological findings
indicate local invasion or, as is the case of large tumors (57),
some studies document good outcomes in cases of
malignant, organ-confined tumors (52,57). Also, there is a
relative contraindication for retroperitoneoscopy if there has
been previous retroperitoneal manipulation or scarring (44).
In these cases, the transperitoneal approach would be more
suitable.
Laparoscopic adrenalectomy can also be performed on
children. Most cases are conducted by the transperitoneal
approach. A non-randomized retrospective multicenter
study showed that this method is a feasible and secure
procedure for young patients, with a 10% conversion rate
(58). Furthermore, when referring to the retroperitoneal
approach, there are few studies indicating that the surgical
positions for adults can also be applied to children.
However, there are no available data related to retro-
peritoneal treatment specifically for PHEO. Most cases are
included in non-specific retroperitoneal adrenalectomy
series (59,60), or even included in adult series, indicating
the feasibility of the method with no major complications,
although right-sided procedures can be technically more
demanding (61).
An important issue concerning the retroperitoneoscopic
technique is how to teach the procedure to those who do not
routinely perform it. A study conducted by Barczynski and
Walz (62) reported the experience of a pioneering group in
this technique who introduced it to an inexperienced group.
The experienced group continuously supervised the student
group and offered direct surgical assistance during the
initial cases. They compared the first cases of each group
and found a significant impact on the operative time and
conversions in the learning group. The recommendation
was that previous visits and contacts to experienced centers,
as well as initial assistance from an experienced surgeon,
can flatten the learning curve of the apprentice surgeons, as
reflected by safer outcomes for patients. It was estimated
that the apprentice had to operate on 20–25 cases under
supervision before being able to perform the procedure in
under a mean operative time of 90 min.
Retroperitoneoscopic adrenalectomy can be indicated for
the treatment of PHEO with the same peri-operative outcomes
as the transperitoneal approach because it allows direct access
to the adrenal glands with no increase in the operative risks.
Although technically more demanding than the transperito-
neal approach, retroperitoneoscopy can shorten the mean
operative time, which is useful for cases of PHEO in order to
minimize intraoperative hemodynamic changes. Blood loss
and convalescence time can be also reduced by this approach.
There is no absolute indication for using either the transper-
itoneal or retroperitoneal approaches; however, the latter
procedure may be the better option for cases with a previous
abdominal surgeries and obese patients.
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